Table 1.

Clinical features, including treatment and follow up, for NTRK-rearranged uterine sarcomas of the cohort.

Case	Age (years)	Presentation	Site	Size (cm)	FIGO Stage	Surgical Therapy or Procedure	Adjuvant Therapy	Recurrence	Time to Recurrence (months)	Follow up (months)	Status
1	35	Anemia, “fibroid”	Corpus	5.1	IB	Myomectomy	NK	NK	NA	NA	LTFU
2	35	Dysmenorrhea, dyspareunia	Cervix	3.5	IA	TAH BSO	NK	NK	NA	NA	LTFU
3	47	Mass	Cervix	7.8	IB	TAH BSO, bilateral pelvic & para-aortic nodes	Radiation & chemotherapy	NK	NA	12	DOD
4	30	Enlarged, vascular, friable cervix	Cervix	4.0	IIB	TAH BS & omentectomy	N	N	NA	35	NED
5	39	NK	Cervix	NK	NK	Local excision	NK	NK	NA	NA	LTFU
6	16	NK	Cervix	NK	IA	Biopsy, LEEP, CKC	N	N	NA	30	NED
7	26	NK	Cervix	12	IIB	TAH BS	Radiation	Pelvis	13	82	NED
8	26	NK	Cervix	5.5	≥IB	TAH	Radiation & chemotherapy	Peritoneum, lymph nodes, bone	6	22	DOD
9	26	NK	Cervix	NK	NK	Local excision	NK	Lung	72	84	DOD
10	61	Vaginal bleeding	Cervix	7	IB	TAH BSO	N	N	NA	16	NED
11	24	NK	Cervix	NK	IA	Local excision	N	N	NA	16.5	NED
12	42	NK	Cervix	NK	NK	Local excision	NK	NK	NA	NA	LTFU
13	42	Vaginal bleeding	Cervix	5.6	IB	TAH BSO	N	N	NA	44	NED
14	46	NK	Cervix	10.0	IB	Radical hysterectomy BSO	Radiation*	NK	NA	NA	LTFU
15	26	Vaginal bleeding	Cervix	8.0	NK	Cervical biopsy	NK	NK	NA	NA	LTFU

^*neoadjuvant radiation therapy; LEEP = loop electrosurgical excision procedure; CKC = cold knife cone biopsy; LTFU = lost to follow up; NED = no evidence of disease; DOD = died of disease; NA = not applicable; NK = not known; TAH = total abdominal hysterectomy; BSO = bilateral salpingo-oophorectomy; BS = bilateral salpingectomy